Trial reportEuropean journal of nuclear medicine and molecular imaging2017
High clinical and morphologic response using
Trial report in European journal of nuclear medicine and molecular imaging, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 2 syntheses or guidelines pooled it, 53 citations in OpenAlex.
- Japan Endocrine Society Clinical Practice Guideline for the Diagnosis and Management of Pheochromocytoma and Paraganglioma 2025.Endocrine journal · 2026Guideline
- Peptide receptor chemoradionuclide therapy for neuroendocrine neoplasms: A systematic review.Journal of neuroendocrinology · 2025Pooled it
- Efficacy and Safety of Lu-177 DOTATATE Peptide Receptor Radionuclide Therapy in Patients with Unresectable or Metastatic Neuroendocrine Tumors in Korea.Targeted oncology · 2024Trial
- Targeted Radionuclide Therapy: Current Landscape and Combination Approaches to Improve Oncology Outcomes.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Review
- Pathological Pathways of Olfactory Neuroblastoma: From Molecular Mechanisms to Targeted Therapy: A Narrative Review.Cancers · 2026Review
- Radionuclide-Labeled Biomaterials: A Novel Strategy for Tumor-Targeted Therapy.Biomimetics (Basel, Switzerland) · 2025Review
- [Importance of peptide receptor radionuclide therapy for the management of neuroendocrine tumours].Radiologie (Heidelberg, Germany) · 2025Review
- Radionuclide-labelled nanoparticles for cancer combination therapy: a review.Journal of nanobiotechnology · 2024Review
- Agonists, Antagonists and Receptors of Somatostatin: Pathophysiological and Therapeutical Implications in Neoplasias.Current issues in molecular biology · 2024Review
- Approach to the Patient: Concept and Application of Targeted Radiotherapy in the Paraganglioma Patient.The Journal of clinical endocrinology and metabolism · 2024Review
- Advances in Radioligand Theranostics in Oncology.Molecular diagnosis & therapy · 2024Review
- A Review of Theranostics: Perspectives on Emerging Approaches and Clinical Advancements.Radiology. Imaging cancer · 2023Review
- Review
- Glucose Metabolism Modification Induced by Radioligand Therapy with [Pharmaceutics · 2022Article
- Theranostics in neuroendocrine tumors: an overview of current approaches and future challenges.Reviews in endocrine & metabolic disorders · 2021Review
- Retrospective study of peptide receptor radionuclide therapy for Japanese patients with advanced neuroendocrine tumors.Journal of hepato-biliary-pancreatic sciences · 2021Article
- Renal and Red Marrow Dosimetry in Peptide Receptor Radionuclide Therapy: 20 Years of History and Ahead.International journal of molecular sciences · 2021Review
- High-Specific-Activity-Clinical cancer research : an official journal of the American Association for Cancer Research · 2021Review
- Theranostic implications of molecular imaging phenotype of well-differentiated pulmonary carcinoid based onEuropean journal of nuclear medicine and molecular imaging · 2021Article
- Current Status and Trends in Peptide Receptor Radionuclide Therapy in the Past 20 Years (2000-2019): A Bibliometric Study.Frontiers in pharmacology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeBulky disease is an adverse prognostic factor for
methodsWe reviewed patients (pts) with at least one lesion of a transaxial diameter >4 cm who completed 1-2 cycles of
resultsTwenty-six pts (17 men; aged 27-74 years) received a median cumulative activity of 6.5 GBq
conclusionPRCRT with
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.